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Gene expressionGlucose deprivation occurs in several human diseases, including infarctions and solid tumors, and leads to cell
death. In this article, we investigate the role of the pseudokinase Tribbles homolog 3 (TRIB3) in the cellular stress
response to glucose starvation using cell lines derived from HEK293, which is highly glycolytic under standard
conditions. Our results show that TRIB3mRNA and protein levels are strongly upregulated in glucose-deprived
cells via the induction of activating transcription factor 4 (ATF4) by the endoplasmic reticulum (ER) stress sensor
kinase PERK. Cell survival in glucose-deﬁcient conditions is enhanced by TRIB3 overexpression and reduced by
TRIB3 knockdown. Genome-wide gene expression proﬁling uncovered approximately 40 glucose deprivation-
responsive genes that are affected by TRIB3, including several genes involved in signaling processes and metab-
olism. Based on transcription factor motif analysis, the majority of TRIB3-downregulated genes are target genes
of ATF4, which TRIB3 is known to inhibit. The genemost substantially upregulated by TRIB3 is insulin-like growth
factor binding protein 2 (IGFBP2). IGFBP2 mRNA and protein levels are downregulated in cells subjected to glu-
cose deprivation, and reduced IGFBP2 expression aggravates cell death during glucose deﬁciency, while overex-
pression of IGFBP2 prolongs cell survival. Moreover, IGFBP2 silencing abrogates the pro-survival effect of TRIB3.
Since TRIB3 augments IGFBP2 expression in glucose-starved cells, the data indicate that IGFBP2 contributes to
the attenuation of cell death by TRIB3. These results implicate TRIB3 and IGFBP2, both of which are known to
be overexpressed in several types of cancers, as pro-survival modulators of cell viability in nutrient-deﬁcient
microenvironments.
© 2015 Published by Elsevier B.V.1. Introduction
Glucose deprivation is a cell death-inducing condition that occurs
during diseases such as cerebral and myocardial infarctions, due to a
blockage of blood ﬂow, and in the central regions of solid tumors, due
to insufﬁcient vascularization.When having the opportunity, malignant
cells tend to consume glucose at a particularly high rate and predomi-
nantly generate energy from glycolysis, which is followed by lactate
production even in aerobic conditions (the Warburg effect) [1]. This
elevation of glucose utilization is readily exploited in the diagnostic
imaging of tumors using 18F-ﬂuorodeoxyglucose positron emission to-
mography [1] and is thought to contribute to the depletion of glucose; eIF2α, eukaryotic translation
lin-like growth factor; IGFBP2,
tetracycline; TRIB3, Tribblesin the tumor interior [2]. Oncogenic activation of proliferative signaling
appears to sensitize cells to glucose deprivation [3], and the inhibition of
glycolysis forms the basis of several cancer treatment strategies investi-
gated at the pre-clinical as well as the clinical level, with compounds
such as 2-deoxyglucose, 5-thioglucose and 3-bromopyruvate being
applied to target different steps of glycolysis [3]. Thus, the cellular
responses to glucose deﬁciency are relevant to tumor growth as well
as anti-cancer therapy.
TRIB3 (also known as TRB3, NIPK, SKIP3, and SINK) is a gene that is
overexpressed in many types of tumors, such as breast, colon, esopha-
gus and lung tumors [4,5], and high TRIB3 mRNA level is associated
with poor prognosis in colorectal and breast cancer patients [6,7]. In
terms of protein structure, TRIB3 is considered to be a pseudokinase,
since it contains a kinase-like domain that is predicted to be catalytically
inactive due to amino acid substitutions [8]. TRIB3 interacts with a
number of different proteins, including cellular stress-associated tran-
scription factors (ATF4, CHOP, C/EBPβ, and NF-κB) and protein kinases
(Akt/PKB, MEK1, MKK7, and MLK3) [9], and appears to regulate
stress-induced cell death by multiple context-dependent mechanisms,
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ferent cell types and stress situations (for example, a pro-survival func-
tion in [7,10–14] and a pro-death function in [15–17]). Further
investigation of the biology of TRIB3 may increase the comprehension
of its dichotomous effects on cell viability and help to bring TRIB3 closer
to clinical applications.
IGFBP2 is one of the six members of the insulin-like growth factor
(IGF) binding protein family, which bind circulating IGF-I or IGF-II,
thereby limiting the bioavailability of IGF and increasing IGF half-life
in plasma [18]. By modulating IGF activity, IGFBPs can affect cell func-
tions that are mediated by the IGF receptor; for example, overexpres-
sion of IGFBP2 in cell culture can inhibit IGF-induced cell proliferation
in low-serum medium [19]. Additionally, IGFBPs also have IGF-
independent functions, which may be exerted intracellularly as well as
extracellularly. In an IGF-independent manner, IGFBP2 is able to inhibit
apoptosis by repressing the expression of procaspase-3 [20] and
increase cell motility by interacting with integrin α5 and activating
integrin signaling [21]. IGFBP2 is overexpressed in multiple malignan-
cies, including colorectal, breast, gastric, pancreatic and ovarian cancer,
leukemia and glioma [22–28]. Moreover, a high in situ level of IGFBP2 is
associatedwith poor prognosis in glioma and leukemia patients [29,30],
and a high serum level of IGFBP2 is a biomarker for poor prognosis in co-
lorectal cancer and glioma patients [31,32].
In the current work, we study the expression and function of
human TRIB3 during glucose deprivation using cells lines derived
from HEK293, which in standard growth conditions exhibits a highly
glycolytic (“glucose-addicted”)metabolic phenotype that is comparable
to tumor cells, consuming glucose at a rate 7-fold greater than that of
the next most utilized carbon source, glutamine, and converting ap-
proximately 80% of the intracellular pyruvate pool into lactate [33].
We determine the effect of TRIB3 on glucose-starved cell survival, and
perform genome-wide gene expression proﬁling to shed light on
TRIB3-induced changes to the glucose deprivation transcriptional re-
sponse. Based on the results of transcriptional proﬁling, further experi-
ments are performed to determine the effect of IGFBP2 on glucose
deprivation-induced cell death and to uncover the relationship between
IGFBP2 and TRIB3 in the cellular response to glucose deﬁciency.
2. Materials and methods
2.1. Cell culture and treatment
T-REx-293 cells (HEK293-derived cell line stably expressing tetracy-
cline (Tet) repressor protein)were obtained from Invitrogen. TRIB3-293
and Vector-293 cells were created by stable transfection of T-REx-293
cells with a Tet-inducible human TRIB3 expression construct and the
corresponding empty vector, respectively [10]. Cells were grown in
IMDM supplemented with 10% FCS and 1× penicillin/streptomycin
(all purchased from PAA) in an atmosphere of 5% CO2 at 37 °C.
For glucose deprivation experiments, cells were seeded onto poly-L-
lysine-coated tissue culture plates. All cells were placed in fresh growth
medium24h before glucosewithdrawal. Tet-regulated gene expression
was activated 24 h prior to the start of glucose starvation by replacing
the culture medium with fresh medium supplemented with 1 μg/ml
Tet. Cell conﬂuency at the onset of glucose deprivation was approxi-
mately 75%. To induce glucose deprivation, cells were washed three
times with PBS and incubated in glucose-free DMEM (without sodium
pyruvate; Gibco) supplemented with 10% dialyzed FCS (Sigma-Aldrich)
and 1×penicillin/streptomycin (PAA). For Tet-treated cells, the glucose-
freemediumwas additionally supplementedwith 1 μg/ml Tet. To obtain
glucose-containing (complete) controlmedium, D-glucosewas added to
the glucose-freemedium at a ﬁnal concentration of 4.5 g/l. Wortmannin
(Calbiochem) and tunicamycin (Sigma-Aldrich) were used at 1 μM and
2.5 μg/ml concentrations, respectively, in the glucose-free or glucose-
containing experimental treatment medium, respectively. To prepare
methionine-deﬁcient growth medium, methionine-free DMEM wasobtained from BioSera and supplemented with dialyzed FCS and antibi-
otics as described above for the preparation of glucose-free medium. To
inhibit PERK (EIF2AK3) activity, cells were pre-incubated with the indi-
cated concentration of PERK inhibitor GSK2606414 (Axon Medchem)
for 45min in fresh growthmedium before the application of the indicat-
ed experimental treatment medium supplemented with the indicated
concentration of PERK inhibitor.
2.2. Transfection of siRNA and plasmid DNA
Transfections were performed 24 h prior to glucose withdrawal,
using the Lipofectamine 2000 transfection reagent (Invitrogen) accord-
ing to themanufacturer's reverse transfection protocol. During transfec-
tion, cells were incubated in Opti-MEM I reduced-serum medium
(Invitrogen) supplemented with 3% FCS (unless speciﬁed otherwise)
on poly-L-lysine-coated tissue culture plates. For plasmid transfection,
500 ng of DNA was used per 24-well plate well (containing 500 μl of
growth medium), and for siRNA transfection, the concentration of
siRNAwas 80 nM(unless speciﬁed otherwise). For both siRNA and plas-
midDNA transfection, 3 μl of transfection reagentwas used permilliliter
of culture medium. The siRNAs targeting TRIB3mRNA and ATF4mRNA
have been described previously [10], and the sequence of the siRNA
targeting IGFBP2 mRNA was 5′-CCUCAAACAGUGCAAGAUGdTdT-3′
(sense strand shown; based on [34]). The AllStars Negative Control
siRNA (Qiagen) was used as a non-targeting negative control siRNA.
The IGFBP2 and BiP overexpression plasmids used in this study are de-
scribed below.
2.3. Plasmid construction
To generate the human IGFBP2 expression plasmid IGFBP2-pCG, the
IGFBP2 coding sequencewas PCR-ampliﬁed fromHEK293 cell line cDNA
using the primers 5′-GCGTCTAGACCATGCTGCCGAGAGTGGGCT-3′ and
5′-GCGGGTACCTACTGCATCCGCTGGGTGTG-3′ (sense and anti-sense,
with XbaI and Acc65I restriction sites underlined, respectively) and
cloned into the pCG vector [35]. The human BiP expression plasmid
BiP-pCG was constructed by the same approach, using the primers 5′-
GCGTCTAGACCATGAAGCTCTCCCTGGTGGC-3′ and 5′-GCGGGTACCACT
AGCAGATCAGTGTCTACAACTCA-3′ (sense and anti-sense, respectively).
Sequencing conﬁrmed that the IGFBP2 and BiP coding sequences in the
respective plasmids correspond to the reference mRNA sequences
(NCBI RefSeq accession codes NM_000597.2 and NM_005347.4,
respectively).
2.4. Real-time PCR quantiﬁcation of gene expression
For RT-qPCR, total RNA was extracted from cells using the TRIzol re-
agent (Invitrogen) according to the manufacturer's recommendations
and quantiﬁed spectrophotometrically using NanoDrop 1000 (Thermo
Scientiﬁc). Total RNA was treated with DNase I and used for ﬁrst strand
cDNA synthesis as described previously [11,36]. Real-time PCRwas per-
formed as reported previously [11] and ribosomal protein L7a (RPL7A)
mRNA was used as the endogenous reference for expression level
normalization. The sequences of the primers used for RT-qPCR are as
follows: TRIB3mRNA: described in [37], TRIB3 unspliced pre-mRNA: de-
scribed in [38], IGFBP2mRNA: 5′-AAGCATGGCCTGTACAACCT-3′ (sense)
and 5′-GGGTTCACACACCAGCACT-3′ (anti-sense), ATF4mRNA: 5′-CCCT
GGCCAAGGAGATCCAGTACCT-3′ (sense) and 5′-ACATTGACGCTCCTGA
CTATCCTCAACT-3′ (anti-sense), and RPL7AmRNA: described in [37].
2.5. Trypan blue exclusion assay
To determine cell viability, the trypan blue dye exclusion method
was used as described previously [10]. In each independent experiment,
viable and non-viable (dye-accumulating) cells were counted from two
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death in the replicate wells was averaged.
2.6. Western blotting
The total protein concentration in cell lysates was determined using
the BCA protein assay kit (Pierce) to allow loading of equal amounts of
total cellular protein in each gel lane. Proteins were separated by SDS-
PAGE in 10% polyacrylamide gel and transferred to Hybond-ECL nitro-
cellulose membrane (Amersham). For the detection of TRIB3 protein,
horseradish peroxidase-conjugated anti-human TRIB3 antibody was
used (1:3000 dilution) [10]. Unconjugated primary antibodies used for
immunoblotting were the following: rabbit anti-human IGFBP2 poly-
clonal antibody (1:1000 dilution; Cell Signaling Technology #3922),
rabbit anti-human ATF4 polyclonal antibody (1:4000 dilution; Santa
Cruz Biotechnology sc-200), rabbit anti-phospho-Akt (Thr308) mono-
clonal antibody (1:3000 dilution; Cell Signaling Technology #2965),
rabbit anti-phospho-Akt (Ser473) polyclonal antibody (1:3000 dilution;
Cell Signaling Technology #9271), and rabbit anti-human β-Tubulin
polyclonal antibody (1:6000 dilution; Abcam ab6046). For the unconju-
gated primary antibodies, goat anti-rabbit IgG horseradish peroxidase-
conjugated secondary antibody was used (1:5000 dilution; Cell Signal-
ing Technology #7074). After incubation with antibody, membranes
were treatedwith Amersham ECL Plus enhanced chemiluminescent de-
tection reagent and proteins were detected by medical X-ray ﬁlm
exposure.
2.7. Genome-wide gene expression proﬁling
For gene expression microarray analysis, TRIB3-293 and Vector-293
cells were subjected to the indicated treatments in duplicate and total
RNA was isolated from the cells using the RNeasy Mini kit (Qiagen).
RNA quality was veriﬁed with the Agilent 2100 Bioanalyzer system
(RNA integrity number: 9.90–10.00). RNA from duplicates was pooled
in equal proportions based on concentration and analyzed with the
Illumina HumanHT-12 v4 BeadChip genome-wide gene expression mi-
croarray according to the manufacturer's instructions. The microarray
data were log2-transformed and quantile-normalized using the
Bioconductor package lumi [39] (version 1.14.0). The probe signal de-
tection P value cutoff was 0.01, and probes not classiﬁed as detected in
any of the samples were discarded. To obtain a high-speciﬁcity set of
gene probes regulated by glucose deprivation in the T-REx-293 lineage
of HEK293 cells, the results from Tet-treated and -untreated Vector-293
and Tet-untreated TRIB3-293 samples were selected for analysis, while
Tet-induced TRIB3-293 sampleswere omitted to exclude possible TRIB3
overexpression-dependent effects (which are the focus of subsequent
analyses). For each probe, data from the cell line demonstrating less
modulation by glucose starvation was retained, and a cut-off of 2-fold
change (either up- or downregulation) was applied. Thus, glucose
deprivation-regulated gene probes were deﬁned as probes regulated
at least 2-fold in response to glucose withdrawal in Vector-293 as well
as Tet-untreated TRIB3-293 cells. This approach lowers the amount of
false-positives arising from cell line-speciﬁc effects and signal measure-
ment error, which would not be robustly offset solely by averaging, due
to the small number of samples in the microarray analysis. The annota-
tions of gene products were obtained from the Gene Ontology project
[40] (database release 2014-09-25). Functional proﬁling analysis of
gene sets was performed with the g:Proﬁler online tool [41] (accessed
2015-02-12) by searching for Gene Ontology terms using an ordered
query and applying hierarchical ﬁltering (best per parent) to the
enriched terms. Transcription factor motif enrichment analysis of gene
sets was carried out with iRegulon software [42] (version 1.2) using
the default settings. The microarray data from the current study has
been deposited into the ArrayExpress public database (http://www.
ebi.ac.uk/arrayexpress/) under the accession code E-MTAB-3318.2.8. Measurement of protein synthesis by 35S-methionine/cysteine
incorporation
Cells were grown in 6-well tissue culture plate wells and incubated
in glucose-free medium or complete medium (control), as described
above. After the indicated amount of time, the cells were incubated in
1 ml medium containing 20 μCi 35S-methionine/cysteine (Perkin-
Elmer) per well for 30 min at 37 °C and 5% CO2. The labeling medium
was prepared using glucose-free DMEM without cystine and methio-
nine (BioSera) but was otherwise identical in composition to the glu-
cose deprivation medium. After pulse-labeling, the cells were washed
with PBS and lysed with 200 μl RIPA buffer. Twentymicroliters of lysate
was applied to Whatman 3MM paper blocked with 0.1% methionine
and 0.1% cysteine, treated with 10% trichloroacetic acid (TCA) for
20 min on ice, boiled in 5% TCA for 15 min, washed once with 5% TCA,
washed once with 96% ethanol, and allowed to dry. 35S incorporation
was measured by liquid scintillation counting using a Tri-Carb 2800TR
instrument (Beckman Coulter) and Optiphase HiSafe 3 scintillation
cocktail (Perkin-Elmer). For each sample, the number of disintegrations
perminutewas normalized to the total protein content of the cell lysate,
which was determined using the BCA protein assay kit (Pierce).
2.9. ATP quantiﬁcation
ATP levels were measured using the luciferase-based ATP Biolumi-
nescence Assay Kit CLS II (Roche) as described previously [10].
2.10. Differential interference contrast microscopy
Cells were transfected with siRNAs and deprived of glucose, as
described above. Cells were incubated on poly-L-lysine-coated tissue
culture plates and visualized directly on the tissue culture plates by
differential interference contrast microscopy using an Olympus IX81
inverted microscope with a 10× objective. Images of the cells were ac-
quired with an ORCA-ER CCD digital camera (Hamamatsu).
2.11. Statistical analysis
Data are presented as the mean ± SD, where applicable, and the
number of independent experiments performed is stated in the ﬁgure
legends. Statistical signiﬁcance of gene ontology term enrichment in
gene lists was evaluated using the default settings of the analysis tool
[41]. Other statistical analyses were conducted using R software
(version 3.0.2; The R Foundation for Statistical Computing) and the sta-
tistical methods used for each analysis are stated in the ﬁgure legends.
One-way ANOVA and two-tailed t tests were used to compare group
means, and P values were corrected for multiple testing using the
Holm–Bonferroni method. For all analyses, P b 0.05 was considered sta-
tistically signiﬁcant.
3. Results
3.1. TRIB3 is transcriptionally induced in response to glucose deprivation
To characterize the regulation of TRIB3 gene expression in response
to glucose deprivation, we incubated T-REx-293 cells (HEK293 cells ex-
pressing Tet repressor) in glucose-free growth medium and quantiﬁed
TRIB3mRNA and pre-mRNA abundance using real-time PCR. The results
show that the TRIB3 mRNA level is rapidly induced following glucose
withdrawal, exhibiting approximately 2-fold upregulation after 3 h of
incubation without glucose, and subsequently, TRIB3 expression con-
tinues to increase, reaching greater than 6-fold induction after 6 h, com-
pared to cells grown in complete medium (Fig. 1A). Next, we utilized
the quantiﬁcation of unspliced pre-mRNA abundance to study gene
transcription rate [43]. As demonstrated in Fig. 1B, the level of TRIB3
unspliced pre-mRNA is substantially upregulated in glucose-starved
Fig. 1. Glucose deprivation upregulates TRIB3 expression. (A) TRIB3mRNA level in T-REx-293 (tetracycline (Tet) repressor-expressing HEK293) cells incubated in glucose-free growth
medium for the indicated amount of time. RT-qPCR was used to quantify mRNA expression, and for each time-point, the mean ± SD from three independent experiments is presented
relative to the average expression level in 0 h glucose-deprived cells. (B) TRIB3 unspliced precursor mRNA level in glucose-deprived T-REx-293 cells. TRIB3 pre-mRNA abundance was
analyzed by RT-qPCR and, for each time-point, themean± SD from three independent experiments is presented relative to the average TRIB3 pre-mRNA level at the time of glucosewith-
drawal (0 h glucose-free). (C) TRIB3 protein level in TRIB3-293 cells after 0 or 24 h of incubation in glucose-free medium. TRIB3-293 cells were generated by stable transfection of T-REx-
293 cells with a Tet-inducible TRIB3 expression construct, and the presence (+) or absence (−) of Tet in the cell culture medium is indicated above the immunoblot. The results are
representative of three independent experiments. (D) Regulation of TRIB3mRNA expression by 24 h glucose deprivation in the presence (+) or absence (−) of Tet in Vector-293 cells
(T-REx-293 cells stably transfected with empty Tet-regulated gene expression vector). The TRIB3mRNA level was determined by RT-qPCR, and the mean ± SD from two individual ex-
periments is shown relative to the expression level in complete medium-grown (Glucose+) cells without Tet. *P b 0.05 compared to the corresponding non-glucose-deprived control
(two-tailed t test followed by Holm–Bonferroni correction).
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of TRIB3mRNA (Fig. 1A), with pre-mRNA induction reaching approxi-
mately 4.5- and 6-fold after 3 and 6 h of glucose deprivation, respective-
ly. Thus, TRIB3 gene expression is promptly activated in response to
glucose deﬁciency by transcriptional regulation.
To elucidate the effects of elevated TRIB3 expression in glucose-
deﬁcient conditions, we employed the TRIB3-293 cell line, which is de-
rived from T-REx-293 cells by stable transfection with a Tet-inducible
TRIB3 expression construct. As shown in Fig. 1C, the amount of TRIB3
protein is greatly increased in cells that have been deprived of glucose
for 24 h, and the addition of Tet into the culture medium further
augments the TRIB3 protein level in TRIB3-293 cells. To conﬁrm that
Tet does not affect TRIB3 expression by unspeciﬁc mechanisms, the
control cell line Vector-293, which is derived from T-REx-293 cells by
stable transfection with an empty Tet-inducible expression vector,
was utilized. Vector-293 cells incubated for 24 h in growth medium
lacking glucose display an approximately 7-fold increase in TRIB3
mRNA abundance, compared to cells incubated in complete medium,
and no signiﬁcant difference in TRIB3 expression is evident in response
to the presence of Tet in complete or glucose-deﬁcient medium in the
empty vector-transfected cells (Fig. 1D).
3.2. The PERK–ATF4 axis mediates the upregulation of TRIB3 during glucose
starvation
It has been shown that in cells treated with tunicamycin or
thapsigargin, pharmacological inducers of ER stress, as well as during
arsenite-induced oxidative stress, the TRIB3 gene is activated by the
binding of ATF4 to a C/EBP–ATF composite site located in the proximal
promoter region [16,44]. To determine if the activation of TRIB3 during
glucose deprivation involves ATF4, we analyzed ATF4 expression inglucose-deprived T-REx-293 cells and performed ATF4 silencing exper-
iments. As shown in Fig. 2A, theATF4protein level is greatly increased in
cells subjected to glucose starvation for 8 or 24 h, and the transfection of
siRNA targeting ATF4 substantially reduces the abundance of ATF4 pro-
tein in glucose-deprived cells. Real-time PCR quantiﬁcation of ATF4
mRNA expression reveals that ATF4 transcript abundance is also upreg-
ulated in response to glucose withdrawal, and conﬁrms the knockdown
of ATF4 by siRNA (Fig. 2B). Importantly, the silencing of ATF4 expression
leads to signiﬁcantly decreased TRIB3mRNA (Fig. 2C) as well as TRIB3
unspliced precursormRNA (Fig. 2D) levels in glucose-starved cells, indi-
cating that ATF4 participates in the transcriptional activation of TRIB3 in
response to glucose deﬁciency.
ATF4 protein production is controlled by the phosphorylation of eu-
karyotic translation initiation factor 2α (eIF2α), which can be carried
out by four stress-sensing kinases (PERK, GCN2, PKR and HRI) that
each recognizes a different set of stress conditions, forming a converging
pathway termed the integrated stress response [45]. The characteristic
activator of PERK is ER stress [45], and since ER stress can occur as a con-
sequence of glucose deﬁciency [3], we wondered whether this was the
mechanism leading to the induction of ATF4 and TRIB3 in glucose-
deprived cells. It has been previously shown that the overexpression
of BiP (GRP78, HSPA5), amajor ER chaperone protein, is able to alleviate
pharmacologically induced ER stress [46]. As depicted in Fig. 2E, BiP
overexpression in T-REx-293 cells suppresses the upregulation of the
ATF4 protein level in response to glucose withdrawal as well as in re-
sponse to treatment with ER stress inducer tunicamycin (positive
control), implicating ER stress in the glucose deprivation-induced up-
regulation of ATF4. To elucidate whether PERK activation is the signal
leading to ATF4 induction in glucose-deprived cells, we utilized the
highly selective PERK inhibitor GSK2606414 [47]. The results reveal
that treatment with PERK inhibitor substantially reduces the ATF4
Fig. 2. TRIB3 induction in glucose-deprived cells ismediated by the activation of the PERK–ATF4 endoplasmic reticulum stress response pathway. (A) ATF4 protein level in T-REx-293 cells
transfected with siRNA targeting ATF4 or non-targeting negative control (NC) siRNA and incubated in either glucose-free growth medium (Glc−) or complete medium (Glc+) for the
indicated amount of time. The immunoblot presented is representative of three independent experiments. (B–D) RT-qPCR quantiﬁcation of ATF4mRNA (B), TRIB3mRNA (C) and TRIB3
unspliced pre-mRNA (D) levels in T-REx-293 cells transfected with ATF4 siRNA or NC siRNA and incubated in growth medium with (+) or without (−) glucose for 8 h. The means ±
SD from three independent experiments are presented relative to the expression levels inNC siRNA-transfected cells grown in glucose-containingmedium. (E) Effect of BiP overexpression
onATF4 protein abundance in T-REx-293 cells incubated in either glucose-containing controlmedium(Glc+), glucose-freemedium (Glc−) or glucose-containingmediumsupplemented
with the ER stress inducer tunicamycin (Tun; 2.5 μg/ml). Prior to the experimental treatment, the cells were transiently transfectedwith either the expression plasmid for humanBiP (BiP-
pCG) or the corresponding empty plasmid vector. The immunoblot shown is representative of two independent experiments. (F) ATF4 protein level in T-REx-293 cells subjected to stress-
ful growth conditions in the absence (−) or presence (+) of 0.8 μMPERK inhibitor GSK2606414. The growthmedium compositions designated Glc+, Glc− and Tun are as in panel E, and
Met− indicates glucose-containing growth medium lacking the essential amino acid methionine. The results presented are representative of two independent experiments. In panels F
and G, gel stained with Coomassie Brilliant Blue is shown below the ATF4 immunoblot to conﬁrm equal protein loading. (G) Efﬁcacy of different concentrations of PERK inhibitor to sup-
press the glucose deprivation-induced upregulation of ATF4 protein level. The results shown are representative of two independent experiments. (H and I) TRIB3mRNA (H) and TRIB3
unspliced pre-mRNA (I) expression levels in T-REx-293 cells that were either treated with PERK inhibitor or mock-treated and incubated in either control medium, glucose-free medium
or growth medium supplemented with 2.5 μg/ml tunicamycin. The expression analyses were performed using RT-qPCR and the mean expression levels ± SD from three independent
experiments are presented relative to the levels in control medium-grown cells without PERK inhibitor treatment. *P b 0.05 comparing NC siRNA- and ATF4 siRNA-transfected samples
(B–D) or PERK inhibitor-treated and -untreated samples (H, I) in matching growth conditions (two-tailed t test followed by Holm–Bonferroni correction).
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cells (Fig. 2F). At the same time, ATF4 protein induction in response to
essential amino acid deprivation (speciﬁcally, methionine deprivation),
which is known to be mediated by the eIF2α kinase GCN2 [45], is unaf-
fected by the presence of PERK inhibitor (Fig. 2F). Comparing differentdoses of PERK inhibitor, a robust impairment of glucose starvation-
induced ATF4 upregulation is evident at concentrations as low as
150 nM (Fig. 2G). In agreement with the inhibition of ATF4 induction,
treatment with PERK inhibitor completely prevents the increase of
TRIB3mRNA level, as well as the activation of TRIB3 gene transcription
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subjected to glucose starvation or tunicamycin treatment (Fig. 2H and
I). Thus, the induction of TRIB3 in glucose-deprived T-REx-293 cells is
mediated by the ER stress sensor kinase PERK via the upregulation of
its downstream transcriptional effector, the transcription factor ATF4.
3.3. TRIB3 expression increases the survival of glucose-deprived cells
Since TRIB3 mRNA and protein were upregulated by glucose deﬁ-
ciency, we proceeded to determine the inﬂuence of TRIB3 on cell surviv-
al. Tet-treated and -untreated TRIB3-293 and Vector-293 cells were
deprived of glucose, and the trypan blue dye exclusion method was
used tomonitor cell culture viability. After 24 h in glucose-freemedium,
the incidence of cell death is low and approximately equal in all of the
different cell populations (Fig. 3A). However, as the duration of the
stress increases, elevated TRIB3 expression is able to promote cell
survival: starting from 48 h, Tet-treated TRIB3-293 cells display signiﬁ-
cantly less cell death compared to TRIB3-293 cells without Tet, with the
difference between Tet-treated and -untreated populations reaching
nearly 2-fold at 72 h (36% and 63% cell death, respectively) (Fig. 3A). Re-
sults from the Vector-293 control cell line verify that the addition of Tet
does not affect sensitivity to glucose starvation by unspeciﬁc mecha-
nisms (Fig. 3A).
To determine the effect of endogenous TRIB3 on glucose-deprived
cell viability, siRNA knockdown experiments were performed in T-
REx-293 cells. At the onset of glucose starvation (0 h), there is no mea-
surable difference in cell death between cultures transfectedwith siRNA
targeting TRIB3 and cultures transfected with non-targeting negative
control siRNA (Fig. 3B). During glucose deprivation, however, TRIB3
knockdown leads to a signiﬁcant increase in cell death after 48, 72 andFig. 3. TRIB3 enhances the viability of cells subjected to glucose starvation. (A) Cell death in glu
left tetracycline-untreated (Tet−). After the indicated amount of time in growthmedium lacki
mean cell death percentage±SD from eight (in the case of 48 and 72 h time-points) or four (24
death in T-REx-293 cells transfectedwith siRNA targeting TRIB3 or non-targeting negative contr
the mean ± SD from four independent experiments. Transfection was performed in IMDM sup
TRIB3 knockdown at the protein level by immunoblot analysis of NC or TRIB3 siRNA-transfected
representative of three independent experiments. (D) RT-qPCR quantiﬁcation of TRIB3 knockdo
sion was analyzed in cells transfected with NC or TRIB3 siRNA and incubated in growth medium
fection experiments is shown (presented relative to the level inNC siRNA-transfected cells). *P b
siRNA-transfected samples (B, D) at the indicated time-point (two-tailed t test followed by Ho96 h in glucose-free medium, compared to control siRNA transfection
(Fig. 3B). Veriﬁcation of TRIB3 knockdown was carried out with
Western blotting and real-time PCR. The results, presented in Fig. 3C
and D, demonstrate that TRIB3 siRNA reduces the TRIB3 protein and
mRNA levels, respectively, in glucose-deﬁcient cells. Thus, in HEK293-
derived cells suffering from glucose deprivation stress, elevated TRIB3
expression increases resistance to cell death.
TRIB3 has been reported to interact with the protein kinase Akt and
block its activation [48]. In certain contexts, Akt activity increases
sensitivity to glucose withdrawal, as revealed by cell viability analysis
of glioblastomacells expressing constitutively active Akt [49]. Therefore,
we studied Akt activation (phosphorylation at positions Thr308 and
Ser473) in Tet-treated and -untreated TRIB3-293 cells at different
time-points during glucose starvation. As demonstrated by the immu-
noblots presented in Supplementary Fig. S1A, the phosphorylation of
Akt at Thr308 as well as Ser473 is similar in glucose-deprived cells
with and without Tet-induced TRIB3 expression. Moreover, treatment
with the PI3K–Akt pathway inhibitor wortmannin does not inﬂuence
the incidence of glucose deprivation-induced cell death in either Tet-
treated or -untreated TRIB3-293 cells (Supplementary Fig. S1B). The
intracellular ATP level can be inﬂuenced by Akt [50] as well as glucose
deﬁciency [3]. As shown in Supplementary Fig. S1C, Tet-induced TRIB3
expression does not alter the ATP level in complete medium-grown
TRIB3-293 cells. As a result of 24 h glucose deprivation, the ATP level
in Tet-treated as well as -untreated TRIB3-293 cells decreases approxi-
mately 4.5-fold, indicating the occurrence of severe bioenergetic stress
and a lack of effect of elevated TRIB3 level on the intracellular ATP
level (Supplementary Fig. S1C). Taken together, these data suggest
that the effect of TRIB3 on cell survival during glucose starvation is not
mediated by Akt.cose-deprived TRIB3-293 and Vector-293 cell cultures treated with tetracycline (Tet+) or
ng glucose, cell culture viability was determined by the trypan blue exclusion method. The
h time-point) independent experiments is presented. (B)Glucose deprivation-induced cell
ol (NC) siRNA. The incidence of cell deathwas quantiﬁed as in A, and the data presented is
plemented with 10% FCS and the concentration of siRNA was 60 nM. (C) Conﬁrmation of
T-REx-293 cells starved of glucose for 24 h. Cells were transfected as in B. The results are
wn efﬁciency T-REx-293 cells during glucose deprivation. The level of TRIB3mRNA expres-
lacking glucose for 24 h. The mean expression level ± SD from three independent trans-
0.05 comparing Tet-treated and -untreated TRIB3-293 samples (A) or NC siRNA- and TRIB3
lm–Bonferroni correction).
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HEK293-derived cells
TRIB3 is present in the nucleus and has been shown to interact with
several diverse transcription factors [9]. Therefore, we sought to inves-
tigate the inﬂuence of TRIB3 on the transcriptional response to glucose
deprivation by performing genome-wide gene expression proﬁling of
TRIB3-293 and Vector-293 cells that were incubated in either glucose-
free medium or complete medium, either in the presence or absence
of Tet.
In order to provide context for the effects of TRIB3, we set out by
evaluating the landscape of transcriptional changes that occur in
glucose-starved HEK293-derived cells. Overall, approximately 19,000
probes yielded detectable signals from a total of more than 47,000
different gene probes on the microarray. Based on microarray samples
without Tet-induced TRIB3 expression (Vector-293 and Tet-untreated
TRIB3-293), the effect of glucose deprivation was calculated for all
detectable probes. The results reveal that TRIB3 (endogenous) ranks as
the most highly regulated gene in response to 24 h of glucose depriva-
tion, displaying an upregulation of more than 10-fold (Fig. 4A; the mi-
croarray probe for TRIB3 is limited to detecting endogenous TRIB3
mRNAby targeting the 3′-UTR). In total, approximately 300 gene probes
are induced and 270 are repressed in response the glucose deﬁciency,
using a cut-off of 2-fold change (Supplementary Tables S1 and S2,
respectively).
To functionally characterize the transcriptome-level response to glu-
cose starvation, we performed Gene Ontology term enrichment analy-
sis. As shown in Supplementary Table S3, glucose deprivation-induced
genes are signiﬁcantly enriched for ER stress response and amino acid
metabolism genes, in agreement with reports that glucose deprivation
leads to ER stress and the activation of the ATF4-mediated amino acid/
nutrient-sensing response [51,52]. Meanwhile, glucose starvation-
repressed genes are signiﬁcantly enriched for cell cycle progression-
associated genes (Supplementary Table S3), which is consistent with
the cessation of cell proliferation in glucose-free medium.
To characterize the regulatory mechanisms behind the glucose
starvation-associated gene expression patterns, we performed tran-
scription factor binding motif enrichment analysis using iRegulon soft-
ware [42]. The results reveal that in glucose deprivation-upregulated
genes, the greatest over-representation occurs for the binding motifFig. 4. Gene expression proﬁling of the effect of TRIB3 on the transcriptional response to glucos
Tet-untreated, were incubated for 24 h in either glucose-free (Glc−) or complete (Glc+) grow
plot comparingGlc− andGlc+geneexpression levels for all geneprobeswith detectable signal
293 samples, while Tet-induced TRIB3-293 sampleswere omitted in order to exclude possible T
signals (gene expression levels) are presented in log2 arbitrary units. The central diagonal line in
fold and 8-fold indicate the thresholds for the respective amounts of change in expression leve
tecting endogenous TRIB3mRNA(probe ILMN_1787815) ismarkedby an enlargeddot and indic
uncover the effect of TRIB3 overexpression on the glucose starvation transcriptional response. F
meeting the criterion is indicated. Glucose deprivation-regulated geneprobes are deﬁned as pro
untreated TRIB3-293 cells. Gene probes are classiﬁed as TRIB3-regulated if the difference in expr
rivation is at least 1.5-fold.shared by ATF and C/EBP transcription factors, and predict that mem-
bers of these families are major direct activators of transcription in the
glucose deprivation response (Supplementary Table S4). In the genes
that are downregulated in response to glucose starvation, the most
over-represented putative regulatory motifs are the binding motifs for
E2F transcription factors (Supplementary Table S5), a family of regula-
tors that is known to have a crucial role in the control of cell cycle pro-
gression [53].
3.5. Glucose deprivation-regulated genes that are downregulated by TRIB3
To uncover the effect of TRIB3 on glucose deprivation-regulated
genes, a series of ﬁltering steps, depicted in Fig. 4B, were performed.
For all genes regulated by glucose deprivation (Supplementary
Tables S1 and S2), the effect of TRIB3 overexpression ongene expression
level in glucose-deprived TRIB3-293 cellswas assessed, and geneprobes
demonstrating at least 1.5-fold difference between Tet-treated and
-untreated cellswere selected. According to this analysis, approximately
8% of glucose deprivation-regulated gene probes are affected by TRIB3
in glucose-starved cells. Among the probes upregulated by glucose dep-
rivation, 1 probe (1 gene) is further upregulated by Tet-induced TRIB3,
while 20 probes (16 genes) are downregulated by exogenous TRIB3
(Fig. 4B). Conversely, among the probes downregulated by glucose dep-
rivation, 3 probes (3 genes) are further downregulated by Tet-induced
TRIB3, while 22 probes (19 genes) are upregulated by exogenous
TRIB3 (Fig. 4B). These results indicate a trend towards the alleviation
of glucose deprivation-induced transcriptional changes by increased
TRIB3 expression.
We have previously shown that TRIB3 inhibits the activity of ATF4
[54], a central activator of the transcriptional control of amino acid avail-
ability [55]. In linewith this, the current analysis identiﬁes several genes
involved in amino acid biosynthesis and transport (ASS1, ASNS, CTH, CBS,
and SLC1A4) among the genes repressed by TRIB3 (Table 1). An over-
representation of genes related to amino acid metabolism is also the
main result of functional proﬁling of TRIB3-downregulated genes
(Supplementary Table S6), and furthermore, transcription factor motif
analysis indicates that the inhibition of ATF4 may be the predominant
mechanism of TRIB3-mediated gene repression, as 84% of TRIB3-
downregulated genes are predicted to be ATF4 target genes (Supple-
mentary Table S7). It has been found that during ER stress, ATF4 activitye deprivation. TRIB3-293 and Vector-293 cells, either treated with tetracycline (Tet) or left
th medium and subjected to genome-wide gene expression microarray analysis. (A) Dot
s. The results are based onTet-treated and -untreated Vector-293 and Tet-untreated TRIB3-
RIB3 overexpression-dependent effects, which are the focus of subsequent analyses. Probe
dicates no difference in gene expression between Glc− andGlc+, and the lines labeled 2-
l in response to glucose deprivation. On the plot, the location of the microarray probe de-
atedwith an arrow. (B) Schematic illustration of themicroarray data analysis performed to
or each of the criteria subsequently applied to ﬁlter the gene probes, the number of probes
bes regulated at least 2-fold in response to glucosewithdrawal inVector-293 aswell as Tet-
ession level between Tet-treated and -untreated TRIB3-293 cells subjected to glucose dep-
Table 1
Glucose deprivation-regulated genes that are affected by TRIB3, based on genome-wide gene expression microarray analysis.
Gene TRIB3 effect
(fold)a
Glc− effect
(fold)b
Deﬁnition Annotationc Probe ID
Tet− Tet+
IGFBP2 2.42 −4.3 −1.8 Insulin-like growth factor binding protein 2 Regulation of signaling ILMN_1725193
PKM2 2.29 −8.7 −3.8 Pyruvate kinase, muscle Glycolysis ILMN_1672650
PGAM4 1.96 −3.2 −1.7 Phosphoglycerate mutase family member 4 Glycolysis ILMN_1691104
LTBP3 1.89 −2.8 −1.5 Latent transforming growth factor beta binding protein 3 Cell communication ILMN_1805395
LRFN4 1.86 −2.6 −1.4 Leucine rich repeat and ﬁbronectin type III domain containing 4 Transmembrane ILMN_1809417
PGAM4 1.86 −3.6 −1.9 Phosphoglycerate mutase family member 4 Glycolysis ILMN_1682953
LOC387763 1.85 4.3 8.0 Hypothetical LOC387763 (predicted) Not annotated ILMN_1677402
HSPE1 1.85 −4.5 −2.5 Heat shock 10 kDa protein 1 Protein folding ILMN_2092536
UCP2 1.84 −4.4 −2.4 Uncoupling protein 2 Metabolic energy generation ILMN_1685625
ATP13A2 1.78 −2.3 −1.3 ATPase type 13A2 Cation transport ILMN_1704164
TUBA1A 1.76 −5.7 −3.3 Tubulin, alpha 1a Cytoskeleton ILMN_1742981
PKM2 1.75 −8.1 −4.7 Pyruvate kinase, muscle Glycolysis ILMN_1775327
FABP5 1.73 −3.3 −1.9 Fatty acid binding protein 5 Lipid metabolism ILMN_1696302
SNRNP70 1.72 −2.5 −1.5 Small nuclear ribonucleoprotein 70 kDa mRNA splicing ILMN_3248113
SLC6A8 1.65 −2.0 −1.2 Solute carrier family 6, member 8 Creatine transport ILMN_1806349
AES 1.62 −3.9 −2.4 Amino-terminal enhancer of split Transcriptional control ILMN_2333107
Hs.4892 1.60 −2.1 −1.3 Homo sapiens clone 24841 mRNA sequence Not annotated ILMN_1849494
DDX12 1.57 −2.8 −1.8 DEAD/H box polypeptide 12 (Predicted) Helicase activity ILMN_1784420
BSG 1.57 −3.5 −2.2 Basigin Cell communication ILMN_1778374
PTMS 1.56 −2.4 −1.6 Parathymosin DNA replication ILMN_1721046
LY6E 1.55 −3.4 −2.2 Lymphocyte antigen 6 complex, locus E Cell communication ILMN_1695404
PKM2 1.53 −4.5 −2.9 Pyruvate kinase, muscle Glycolysis ILMN_2366634
LOC643856 1.53 −2.2 −1.4 Similar to hCG2026922 (predicted) Not annotated ILMN_3202885
C15orf17 −1.51 2.3 1.5 Chromosome 15 open reading frame 17 Not annotated ILMN_1657744
MTHFD2 −1.53 3.7 2.4 Methylenetetrahydrofolate dehydrogenase 2 One-carbon metabolism ILMN_2405521
PLA2G4C −1.56 3.1 2.0 Phospholipase A2, group IVC Lipid metabolism ILMN_1810191
LARP6 −1.57 3.1 2.0 La ribonucleoprotein domain family, member 6 Regulation of translation ILMN_1752810
SLC1A4 −1.60 2.2 1.4 Solute carrier family 1, member 4 Amino acid transport ILMN_1656904
CALCB −1.64 3.7 2.2 Calcitonin-related polypeptide beta Cell communication ILMN_2109371
TAC1 −1.65 2.7 1.6 Tachykinin Cell communication ILMN_2384409
SH3BGRL −1.65 −2.3 −3.9 SH3 domain binding glutamic acid-rich protein like Regulation of signaling ILMN_1702835
PSMA2 −1.68 −2.1 −3.5 Proteasome subunit, alpha type, 2 Proteolysis ILMN_2058512
MTHFD2 −1.72 4.2 2.4 Methylenetetrahydrofolate dehydrogenase 2 One-carbon metabolism ILMN_1674706
PCK2 −1.73 5.0 2.9 Phosphoenolpyruvate carboxykinase 2 Gluconeogenesis ILMN_1671791
ZCCHC7 −1.76 2.5 1.4 Zinc ﬁnger, CCHC domain containing 7 Nucleic acid binding ILMN_1744980
CBS −1.79 4.3 2.4 Cystathionine-beta-synthase Cysteine biosynthesis ILMN_1804735
CTH −1.80 2.7 1.5 Cystathionase Cysteine biosynthesis ILMN_2305112
PM20D2 −1.83 −3.0 −5.5 Peptidase M20 domain containing 2 Hydrolase activity ILMN_1766000
ASNS −1.86 6.3 3.4 Asparagine synthetase Asparagine biosynthesis ILMN_1796417
ASS1 −1.92 3.8 2.0 Argininosuccinate synthetase 1 Arginine biosynthesis ILMN_1708778
ASNS −1.94 2.5 1.3 Asparagine synthetase Asparagine biosynthesis ILMN_2398107
FUT1 −2.01 2.5 1.3 Fucosyltransferase 1 Protein glycosylation ILMN_1712894
ASS1 −2.02 4.2 2.1 Argininosuccinate synthetase 1 Arginine biosynthesis ILMN_2395451
NUPR1 −2.22 4.2 1.9 Nuclear protein, transcriptional regulator, 1 (=P8) Transcriptional control ILMN_2404688
P8 −2.38 5.4 2.3 p8 protein (=NUPR1) Transcriptional control ILMN_1810560
INHBE −2.91 14.1 4.9 Inhibin, beta E Growth factor activity ILMN_1811767
a Difference in gene expression between tetracycline (Tet)-induced and -uninduced TRIB3-293 cells incubated in glucose-free growth medium for 24 h. Gene probes regulated at least
1.5-fold by Tet-induced TRIB3 expression and at least 2-fold by glucose deprivation (in samples without Tet-induced TRIB3 expression) are presented.
b The effect of 24 h glucose deprivation (Glc−) on gene expression in the absence or presence of Tet (Tet− and Tet+, respectively) in TRIB3-293 cells.
c Annotation terms from the Gene Ontology database.
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Sincewe observed the activation of the ER stress response in the glucose
deprivation gene expression proﬁle (Supplementary Table S3), we in-
vestigated whether TRIB3 affects total protein synthesis by performing
35S-methionine/cysteine pulse labeling of Tet-treated and -untreated
TRIB3-293 cells in complete or glucose-free growthmedium. As demon-
strated in Supplementary Fig. S2, in Tet-untreated cells deprived of glu-
cose for 1–36 h, total protein synthesis is reduced to about 70% of the
rate in complete medium, and protein production sharply declines
after that, reaching approximately 25% of the complete medium rate
after 48 h of glucose deprivation. TRIB3 overexpression does not signif-
icantly alter the rate of protein synthesis in either complete medium or
glucose-free medium (Supplementary Fig. S2). Thus, while serving to
validate the data analysis approach, the blunted expression of amino
acid metabolism-related genes by increased TRIB3 expression does
not lead to changes in the overall translation rate that could possibly ex-
plain the effect of TRIB3 on glucose-deprived cell viability.In addition to amino acid metabolism genes, TRIB3-repressed genes
include several other metabolic enzymes, including FUT1, PM20D2,
PCK2,MTHFD2 and PSMA2, as well as several factors involved in signal-
ing processes, including INHBE, SH3BGRL, TAC1 and CALCB (Table 1). The
latter group includes the gene most substantially inﬂuenced by TRIB3,
the TGF-β superfamily member INHBE, which is inhibited nearly 3-
fold by Tet-induced TRIB3 during glucose starvation (Table 1).
3.6. Glucose deprivation-regulated genes that are upregulated by TRIB3
The genes upregulated by elevated TRIB3 expression in glucose-
starved cells belong to diverse functional classes, including several
genes involved in energy metabolism (such as PKM2, PGAM4, UCP2,
FABP5, and SLC6A8) and several factors involved in signaling processes
(such as IGFBP2, BSG, and LY6E) (Table 1). PKM2 (which encodes pyru-
vate kinase isozyme M2) is the most highly glucose deprivation-
downregulated gene in Tet-untreated TRIB3-293 cells, nearly 9-fold,
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TRIB3 (Table 1). Among glucose deprivation-inhibited genes, the impact
of TRIB3 ismost prominent towards the level of IGFBP2— an insulin-like
growth factor binding protein that is linked to cancer progression [18]—
which is repressed 4.3-fold by glucose deprivation in TRIB3-293 cells
without Tet treatment and merely 1.8-fold when Tet is present
(Table 1). DNA motif enrichment analysis for TRIB3-upregulated genes
suggests several transcription factors as direct regulators that each pos-
sess approximately one-third of the gene set as predicted targets, with
the transcription factors PAX6, BCL6 and HSF1 displaying the highest
enrichment scores (Supplementary Table S8).
In our gene expression proﬁling experiments, we did not detect
the inﬂuence of TRIB3 on genes that are central to the initiation and
execution of cell death programs (such as Bcl-2 family members,
death receptors, or caspases). The results obtained from genome-wide
gene expression proﬁling show that the induction of TRIB3 is among
the most signiﬁcant gene expression changes that occurs in response
to glucose starvation and reveals a subset of glucose deprivation-
regulated genes that are modulated by TRIB3.
3.7. IGFBP2 mRNA and protein levels decrease in response to glucose
deprivation
From the TRIB3-regulated genes revealed by expression proﬁling,
we decided to study IGFBP2 further because of its signiﬁcant clinical
associations (see the Introduction section) and its relatively substantial
TRIB3-dependence according to our microarray data. To determine the
time course of IGFBP2mRNA expression regulation in response to glu-
cose deprivation, T-REx-293 cells were incubated in glucose-free
growthmedium for up to 72 h and the level of IGFBP2mRNAwas quan-
tiﬁed by real-time PCR. As depicted in Fig. 5A, IGFBP2mRNA abundance
after 3 h of glucose starvation is unchanged from 0 h, however, after 6 h
inmedium lacking glucose, the level of IGFBP2mRNA is decreased 2-fold
compared to the level in complete medium-incubated cells. At the 12
and 24 h time-points, IGFBP2mRNA abundance remains relatively un-
changed compared to 6 h, remaining at approximately 50% of its non-
starved level (Fig. 5A). After 48 and 72 h without glucose, IGFBP2
mRNA expression level is more than 5-fold below the level in complete
medium (Fig. 5A). The repression of IGFBP2 in response to glucose dep-
rivation is also detectable at the protein level, as demonstrated in
Fig. 5B.
3.8. Reduced IGFBP2 expression aggravates cell death during glucose
starvation
Having determined that IGFBP2 is robustly downregulated in re-
sponse to glucose deprivation, we decided to investigate whether
IGFBP2 inﬂuences the viability of cells suffering from glucose deﬁ-
ciency. For this purpose, we transfected T-REx-293 cells with siRNA
targeting IGFBP2 or a negative control siRNA, and monitored cell death
in cultures with either glucose-free or complete growth medium. TheFig. 5. Glucose deprivation represses the expression of IGFBP2. (A) IGFBP2mRNA expression le
point, mRNA expression was quantiﬁed by RT-qPCR, and the mean ± SD from two independe
starvation (0 h). (B) IGFBP2 protein level after 0 and 36 h of glucose deprivation in T-REx-293 c
siRNA, as indicated above the immunoblot. *P b 0.05 compared to 0 h glucose deprivation sam
correction for multiple testing using the Holm–Bonferroni method).results reveal that before the onset of glucose deprivation, the viability
of IGFBP2 knockdown cells does not differ from that of control siRNA-
transfected cells, whereas after 72 h of glucose deprivation, the inci-
dence of cell death is signiﬁcantly higher in cells transfected with
IGFBP2 siRNA (52%) than in control siRNA-transfected cells (27%), and
a similar effect is apparent at 96 h (Fig. 6A). The knockdown of IGFBP2
was conﬁrmed at the mRNA and protein levels, as shown in Figs. 6B
and 5B, respectively.
To examine whether IGFBP2 overexpression leads to increased cell
survival during glucose starvation, T-REx-293 cells were transfected
with different amounts of IGFBP2 expression plasmid (using empty
vector to equalize the total amount ofDNA transfected) and cell viability
wasmonitored during incubation in glucose-free medium. After 72 h of
glucose deprivation, cells that received only empty vector exhibit 48%
cell death, while cells transfected with varying amounts of IGFBP2 ex-
pression construct display 27–37% cell death, depending on the amount
of expression plasmid transfected, representing a signiﬁcant decrease in
cell death as a result of IGFBP2 overexpression (Fig. 6C). Similar results
are obtained for cells deprived of glucose for 96 h, and at both time-
points, transfecting very high amounts of IGFBP2 expression plasmid
tends to lessen the pro-survival effect compared to moderate doses
(Fig. 6C). Thus, the level of endogenous IGFBP2 signiﬁcantly contributes
to the survival of glucose-deprived T-REx-293 cells, and in agreement
with this, IGFBP2 overexpression is able to prolong cell survival.
3.9. Elevated TRIB3 expression increases the level of IGFBP2 in
glucose-deprived cells
Since we established that IGFBP2 is a determinant of cell survival
during glucose deﬁciency and our gene expression microarray results
indicated that TRIB3 affects IGFBP2 mRNA level in glucose-deprived
cells, we decided to perform further experiments to examine the regu-
lation of IGFBP2 expression by TRIB3. Western blotting was used to
study IGFBP2 protein levels in TRIB3-293 and Vector-293 cells treated
with Tet or left Tet-untreated. The results, presented in Fig. 7A, demon-
strate that Tet treatment does not signiﬁcantly alter the level of IGFBP2
protein expression in TRIB3-293 cells in the presence of glucose or after
12 h of glucose deprivation, however, after being deprived of glucose for
48 h, the abundance of IGFBP2 protein in TRIB3-293 cells is substantially
greater in Tet-treated cells compared to cells not treated with Tet. Im-
portantly, in Vector-293 cells subjected to glucose starvation for 48 h,
the presence of Tet does not lead to a rise in IGFBP2 expression com-
pared to cells without Tet (Fig. 7A), indicating that increased IGFBP2
level in TRIB3-293 cells is due to elevated TRIB3 expression and not
caused by unspeciﬁc effects of Tet. Using real-time PCR, the level of
IGFBP2mRNA expression was quantiﬁed in TRIB3-293 and Vector-293
cells treated with Tet or left Tet-untreated and incubated in either
glucose-free or complete medium. In the presence of glucose, Tet has
no signiﬁcant effect on IGFBP2 mRNA expression in either TRIB3-293
or Vector-293 cells (Fig. 7B and C). After approximately one day of
glucose deprivation, IGFBP2 mRNA abundance declines approximatelyvel in T-REx-293 cells deprived of glucose for the indicated amount of time. For each time-
nt experiments is presented relative to the average expression level at the start of glucose
ells transfected with either siRNA targeting IGFBP2 or non-targeting negative control (NC)
ples (one-way ANOVA followed by two-tailed comparisons of all time-points to 0 h, with
Fig. 6. IGFBP2 expression promotes cell survival during glucose deﬁciency. (A) Cell death in glucose-deprived T-REx-293 cells transfected with siRNA targeting IGFBP2 or with non-
targeting negative control (NC) siRNA. At the indicated time-points, the trypan blue dye exclusion method was used to determine the viability of glucose-deprived cell cultures, and
themean cell death percentage±SD from three independent experiments is presented. (B) Efﬁciency of IGFBP2mRNAknockdown inT-REx-293 cells after 0 and24h of glucose starvation.
RT-qPCRwas used to quantify the IGFBP2mRNA level in the cell populations studied in panel A (three independent transfections). Data is presented as the mean± SD relative to the av-
erage level inNC siRNA-transfected cells not starved of glucose. (C) Effect of IGFBP2 overexpression on glucose deprivation-induced cell death in T-REx-293 cells. The cellswere transfected
with the indicated amounts of human IGFBP2 expression plasmid (IGFBP2-pCG) per well in 24-well tissue culture plates. The total amount of DNA transfected per well was adjusted to
500 ng using empty vector. After incubation in glucose-free growth medium for the indicated amount of time, cell culture viability was determined with the trypan blue exclusion
assay and the mean percentage of cell death ± SD from three independent experiments is shown. *P b 0.05 comparing corresponding NC siRNA and IGFBP2 siRNA treated samples
(A, B; two-tailed t test followed by Holm–Bonferroni correction) or comparing samples transfected with the indicated amount of IGFBP2-pCG to samples transfected with empty vector
only (C; for each time-point, one-way ANOVA followed by two-tailed comparisons to 0 ng IGFBP2-pCG group with Holm–Bonferroni multiple testing correction).
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however, IGFBP2 mRNA expression in Tet-treated TRIB3-293 cells is
approximately 2-fold greater than in Tet-untreated TRIB3-293 cells
(Fig. 7B and C). Thus, the elevation of IGFBP2 protein level in glucose-
starved cells by increased TRIB3 expression involves the upregulation
of IGFBP2mRNA.
3.10. The pro-survival effect of TRIB3 is IGFBP2-dependent
To shed light on the relationship between TRIB3 and IGFBP2 in the
determination of cell survival, we concurrently manipulated the levels
of TRIB3 and IGFBP2, and tracked cell viability during glucose deﬁciency.
In the ﬁrst experiment, TRIB3-293 cells were transfected with either
IGFBP2 siRNA or negative control siRNA, and either treated with Tet to
induce TRIB3 expression or left Tet-untreated. In cells transfected with
negative control siRNA, 72 h of glucose starvation resulted in signiﬁ-
cantly less cell death in Tet-treated cells, compared to Tet-untreated
cells (Fig. 8A), which is in linewith the pro-survival effect of TRIB3 dem-
onstrated in Fig. 3A. At the same time, in cells transfected with IGFBP2
siRNA, the presence of Tet does not affect cell viability, and the percent-
age of cell death in both Tet-treated and -untreated cells is greater than
in negative control siRNA-transfected cells (Fig. 8A). Thus, in cells with
diminished IGFBP2 expression, TRIB3 overexpression is unable to con-
vey enhanced viability.
In order to investigate the interaction of endogenously expressed
TRIB3 and IGFBP2 on the viability of glucose-deprived cells, we
transfected T-REx-293 cells with combinations of negative control
siRNA, TRIB3 siRNA and IGFBP2 siRNA, and monitored cell survival and
morphology. For each combination of siRNAs, the total amount of
transfected siRNA was equalized by adjusting the amount of negative
control siRNA. As shown in Fig. 8B, cell death in cultures with individual
or concurrent knockdown of TRIB3 and IGFBP2 is similar at the start ofglucose deprivation (0 h). After 72 h of incubation in glucose-freemedi-
um, the percentage of cell death is approximately 2-fold greater in cells
transfected with TRIB3 or IGFBP2 siRNA, compared to cells transfected
with negative control siRNA alone, and importantly, the simultaneous
knockdown of TRIB3 and IGFBP2 does not further impair cell survival
compared to the knockdown of the genes individually (Fig. 8C). When
grown in complete medium, the knockdown of TRIB3 and/or IGFBP2
does not grossly alter the morphology of T-REx-293 cells, with the
cells of all siRNA combinations displaying a similar appearance
(attached to substrate, polygonal in shape) after 48 h, as determined
by differential interference contrast microscopy (Fig. 8D). The with-
drawal of glucose for 72 h causes the morphology of control siRNA-
transfected cells to become more elongated in shape, and while some
rounded and detached cells are also present among the cells transfected
with control siRNA, cell rounding and detachment is much more
prevalent among the cells subjected to individual or simultaneous
knockdown of TRIB3 and IGFBP2 (Fig. 8D). Taken together, these results
demonstrate that TRIB3-mediated repression of glucose deprivation-
induced cell death is dependent on IGFBP2 expression.
4. Discussion
In the interior of solid tumors, cells suffer from glucose deﬁciency as
a result of insufﬁcient nutrient supply due to poorly developed vascula-
ture, excessive proliferation and metabolic abnormalities [1,2,57]. For
instance, in human colon tumors, the glucose concentration has been
found to be on average 10-fold lower than in normal colon tissue,
while the levels of free amino acids are unchanged or even moderately
elevated in the tumor tissue [2]. An increased demand for glucose and a
metabolic switch to aerobic glycolysis are considered hallmarks of ma-
lignant cells [58], and pharmacologically inhibiting glycolysis, effective-
ly starving cancer cells of glucose, presents a promising therapeutic
Fig. 7. IGFBP2 expression during glucose deprivation is enhanced by elevated TRIB3
expression. (A) IGFBP2 protein level in tetracycline (Tet)-treated (+) or Tet-untreated
(−) TRIB3-293 and Vector-293 cells incubated in glucose-free (Glc−) or complete
(Glc+) growthmedium for the indicated amount of time. The results shown are represen-
tative of four independent experiments. (B and C) IGFBP2mRNA expression in TRIB3-293
(B) or Vector-293 (C) cells in complete medium and during glucose starvation. The cells
were incubated for the indicated amount of time in growth mediumwith (+) or without
(−) glucose, either with (+) or without (−) Tet, and mRNA expression was quantiﬁed
using RT-qPCR. Themean IGFBP2 expression level±SD is presented relative to the expres-
sion level in cells incubated inmediumwith glucose and without Tet. The results present-
ed are representative of six (TRIB3-293 without glucose), three (TRIB3-293 with glucose)
or two (Vector-293) experiments. *P b 0.05 comparing Tet-treated and -untreated TRIB3-
293 samples (B) or comparing glucose-deprived samples to the corresponding non-
glucose-deprived controls (C) using the two-tailed t test followed by Holm–Bonferroni
correction.
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eases. For example, in the mouse stroke model involving middle cere-
bral artery occlusion, glucose levels in the infarction core region are
decreasedmore than 10-fold compared to basal levels [59]. Howquickly
glucose deﬁciency, either endogenous or therapeutically-induced, leads
to cell death, depends on the outcome of stress response signaling. In
the present article, we have used cells from the glycolysis-preferring
HEK293 lineage to demonstrate that TRIB3, previously reported to be
overexpressed in several cancers, is highly glucose deprivation-
inducible and that TRIB3 upregulation during glucose starvation delays
cell death. Further analysis led us to uncover IGFBP2 as a pro-survival
factor, the expression of which is repressed by glucose deprivation
and de-repressed by elevated TRIB3 expression.
Our results revealed that TRIB3 pre-mRNA, mRNA and protein levels
are increased upon glucose withdrawal, and that on a genome-wide
scale, TRIB3 mRNA is among the most highly glucose deprivation-
regulated transcripts. Glucose deﬁciency impairs several aspects of cell
function and may lead to, for instance, bioenergetic stress (reduction
of ATP level), oxidative stress (due to decreased NADPH level caused
by pentose phosphate pathway inactivity) and ER stress (due to
impaired protein folding in the ER caused by a lack of glycosylation sub-
strates) [3]. In linewith this, functional proﬁling of glucose deprivation-
induced genes from our experiment revealed a strong enrichment for
ER stress genes. It has been shown previously that TRIB3 is upregulated
in cells suffering from ER stress or oxidative stress, and in both cases the
mechanism of TRIB3 induction was shown to be promoter activation by
ATF4 [16,44]. ATF4 is one of the three proximal transcriptional transduc-
ers of the ER stress response (also termed the unfolded protein re-
sponse), along with ATF6 and XBP1 [51]. Since glucose deprivation caninvoke ER stress, as described above, we hypothesized that TRIB3 induc-
tion during glucose starvation may be mediated by ATF4. Based on our
data, glucose deprivation indeed results in substantially increased
ATF4 protein level, which in turn leads to the induction of TRIB3 in
glucose-deprived cells. Furthermore, we uncovered that the upregula-
tion of ATF4 in response to glucose starvation requires the activity of
the ER stress sensor kinase PERK, indicating that ER stress is the factor
which evokes the upregulation of ATF4 and TRIB3 in cells suffering
from glucose deﬁciency. Intriguingly, in cell cultures, TRIB3 is also up-
regulated in response to hypoxia [4,7], which generally accompanies
glucose deﬁciency in the intra-tumor microenvironment [57]. There-
fore, the overexpression of TRIB3 in tumors [4,5] may be a convergent
response to multiple stressful environmental factors.
By performing silencing of endogenous TRIB3 expression as well as
TRIB3 overexpression experiments, we uncovered that elevated TRIB3
expression in glucose-deﬁcient conditions conveys a substantial surviv-
al advantage in HEK293-derived cells. The increased nutritional stress
resistance afforded by TRIB3 expression could underlie the association
between high tumor TRIB3 expression level and poor prognosis in colo-
rectal cancer patients [6], andmay also have implications for the variety
of other tumor types that have been found to overexpress TRIB3 com-
pared to normal tissue [4,5]. Cell death rescue mechanisms of “glu-
cose-addicted” cells subjected to glucose deprivation may also be
relevant in the context of cancer therapies that aim to inhibit glycolysis,
a ﬁeld that is currently actively investigated [3]. To clarify how TRIB3
augments glucose-deprived cell survival, we examined the effect of ele-
vated TRIB3 expression on the transcriptional response to glucose star-
vation using genome-wide gene expression proﬁling. Our analysis
revealed a diverse set of approximately 40 genes that are regulated by
glucose deprivation and further regulated by TRIB3 during glucose
starvation. The fraction of TRIB3-sensitive genes among glucose
deprivation-sensitive genes is less than 10%, indicating that TRIB3 is
not a broad regulator of the transcriptional response to glucose starva-
tion but rather it modulates the expression levels of a speciﬁc group of
genes, a large portion of which are controlled by ATF4.
In our microarray experiment, one of the genes downregulated in
response to glucose starvation is IGFBP2, and further experiments
conﬁrmed the repression of IGFBP2 in glucose-deprived cells at both
the mRNA and protein level. The molecular mechanisms that underlie
the regulation of IGFBP2 abundance by TRIB3 are currently unclear.
Our analysis of transcription factor motifs in the subset of glucose
deprivation-regulated genes that are upregulated by TRIB3 revealed
BCL6, a transcriptional repressor [60], as oneof themost highly enriched
transcription factors, and predicted that IGFBP2 is a BCL6 target gene. In-
terestingly, amass spectrometry-based search for BCL6-interacting pro-
teins has found that TRIB3 forms a complex with BCL6 [61]. Several
other transcription factors are known to bind to TRIB3, leading to the
inhibition of their activity [16,54,62,63]. It is currently not known
whether and how the formation of a complex between BCL6 and
TRIB3 affects the transcriptional properties of BCL6, and whether an in-
teraction with TRIB3 could lead to the de-repression of BCL6 target
genes. Further studies using the silencing and overexpression of BCL6
are necessary in order to elucidate the possible role of BCL6 in the regu-
lation of IGFBP2 expression and to characterize the effect of BCL6 on cell
viability during glucose starvation. Additionally, our regulatory motif
enrichment analysis implicated several other transcription factors in
glucose deﬁciency-induced gene expression regulation, and the further
characterization of their roles is imperative to increasing our under-
standing of the transcriptional control of the stress response to glucose
deprivation.
Previous research has revealed that IGFBP2 has remarkably diverse
modes of action (e.g. endocrine, paracrine, and intracellular/nuclear;
IGF receptor-dependent and -independent) [18] and, in different bio-
logical contexts, IGFBP2 is able to either suppress [20,64] or facilitate
[65] cell death. In the case of glucose starvation, our results show that
endogenously produced IGFBP2 is a substantial positive modulator of
Fig. 8. The cell viability-enhancing effect of TRIB3 during glucose starvation is IGFBP2-dependent. (A) Cell death in tetracycline (Tet)-treated (+) or Tet-untreated (−) TRIB3-293 cells
transfected with siRNA targeting IGFBP2mRNA or with non-targeting negative control (NC) siRNA and subjected to 72 h of glucose deprivation. The trypan blue dye exclusion method
was used to determine cell culture viability, and the mean percentage of cell death ± SD is presented from three independent experiments. (B and C) Cell death in T-REx-293 cells
with individual or concurrent knockdown of TRIB3 and IGFBP2. Cells were transfected with the indicated concentrations of TRIB3 and IGFBP2 siRNA, and in each case, the overall concen-
tration of siRNA was adjusted to 80 nMwith NC siRNA. The proportion of viable cells was determined at the onset of glucose deprivation (B) and after 72 h of incubation in glucose-free
growth medium (C). The percentage of viable cells was determined with the trypan blue exclusion assay, and the mean ± SD from three independent experiments is displayed. (D) Cell
morphology of T-REx-293 cells subjected to single or double knockdown of TRIB3 and IGFBP2. The concentrations of the siRNAs targeting TRIB3 and IGFBP2were 40 nM, and the total con-
centration of siRNA in the transfectionmixturewas adjusted to 80nMwithNC siRNA. After incubation in complete or glucose-freemedium for the indicated amount of time, the cellswere
examined using differential interference contrast microscopy. The images presented are representative of four independent experiments. Scale bar: 50 μm. The means marked with dif-
ferent letters are signiﬁcantly different at the 5% signiﬁcance level (pairwise comparisons between all groups using two-tailed t tests followed by correction for multiple testing using the
Holm–Bonferroni method).
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sion in response to glucose deﬁciency represents a mechanism for
evoking stress-induced cell death. Intriguingly, our results revealed
that increased expression of TRIB3 is able to alleviate the repression of
IGFBP2 during glucose deprivation, thereby providing a mechanism to
defer cell death. Colorectal and breast tumors have been shown to
overexpress IGFBP2 as well as TRIB3 [6,7,22,23], raising the possibility
that, similar to our results from cells subjected to glucose depriva-
tion, high TRIB3 expression in these types of tumors may contribute to-
wards the observed overexpression of IGFBP2, which could support
malignant cell survival. The mechanism employed by IGFBP2 protein,
upregulated by TRIB3, to increase the viability of glucose-deprived
cells is currently obscure. IGFBP2 has been found to downregulate the
level of procaspase-3 protein and caspase-3 activity, and in this way to
contribute to the inhibition of apoptosis [20]. Interestingly, Shimizu
et al. [14] have recently reported that TRIB3 prevents cytoplasmic acti-
vation of caspase-3 by promoting procaspase-3 entry into the nucleus,
thereby inhibiting apoptosis. Thus, the characterization of TRIB3 and
IGFBP2 effects on (pro)caspase-3 level, location and activitymay uncov-
er an additional level of association between TRIB3 and IGFBP2 in defer-
ring the instigation of cell death in glucose-starved cells.
In conclusion, we have shown that TRIB3 is highly induced in
response to glucose deprivation in cells of the glycolysis-inclined
HEK293 lineage, and that increased expression of TRIB3 enhances cellviability in glucose-deﬁcient conditions. Further, we established that
IGFBP2 is a positive modulator of glucose-deprived cell survival that
undergoes marked downregulation during glucose deﬁciency. Elevated
expression of TRIB3 is able to augment IGFBP2 level in cells suffering
from glucose starvation, and the silencing of IGFBP2 abolishes the pro-
survival effect of TRIB3, implicating IGFBP2 in the mechanism of
TRIB3-mediated cell survival.
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